NEW Financial Headlines Page and Summary Report
We are launching a new Financial Headlines webpage and summary report available on request to stakeholders. The RDTC produces 3 financial headlines reports – Monthly Financial Headlines, Top 50 BNF sections and drugs, Price Concessionary Bulletin – with a wide range and comprehensive set of financial data for users to interrogate, and we thought it might be useful to provide a report which summarises the headline information from within each of these in a short, compact, easy to read format.
This report is available on request summarising the North of England ICBs financial position or the data for each of the SICBLs within your ICB. A free version available for download summarising the national regional position can be found on our new Financial Headlines webpage for download. On this page we will keep you informed of any new updates to our reports, links to any other relevant RDTC publications and any relevant financial headline news.
If you would like a copy of the new financial headlines summary report or have any comments, queries and feedback, please contact us at nuth.nyrdtc.rxsupp@nhs.net.
Formulary amendments March 2026 & horizon scanning April 2026
Two new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in March 2026:
- Monthly formulary amendments – March 2026
- Monthly horizon scanning – April 2026
Formulary assessment – levodopa inhalation powder (Inbrija)
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
The information in this document is correct at the time of publication and formulations may change. This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
The Formulary Assessment tool for inhaled levodopa can be accessed here
Formulary amendments February 2026 & horizon scanning March 2026
Two new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in February 2026:
- Monthly formulary amendments – February 2026
- Monthly horizon scanning – March 2026
Switching from disposable to reusable insulin pens
This document outlines the benefits of appropriate switching from disposable to reusable insulin pens, highlighting advantages for patients, the environment, and potential cost savings. It also provides practical recommendations for implementation by medicines optimisation teams
The switching from disposable to reusable insulin pens bulletin can be accessed here
Electronic repeat dispensing (eRD): medicines roadmap and outcomes of high eRD uptake
Strategic Insight reports are designed to support strategic objectives and planning by Integrated Care System (ICS) leaders. Through the analysis of data and communication with key stakeholders across the ICS, interventions to be undertaken by the ICS are proposed to Integrated Care Boards or associated committees.
This report provides a medicines roadmap to support the uptake and implementation of electronic repeat dispensing (eRD). It also presents the results of an analysis on the impact of high levels of eRD implementation on prescribing volume and hospital admissions.
The eRD medicines roadmap strategic insight report can be accessed here
Formulary amendments January 2026 & horizon scanning February 2026
Two new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in January 2026:
- Monthly formulary amendments – January 2026
- Monthly horizon scanning – February 2026
Principles for embedding pharmacogenomics into NHS medicines governance
Pharmacogenomics (PGx) is a key component of personalised medicine. The purpose of this bulletin is to introduce PGx to medicines committees and working groups and provide considerations for embedding PGx testing into medicines governance structures and processes, supporting the safe and effective use of medicines.
This document was updated on 5th of February 2026 with minor text revisions to improve clarity.
Formulary assessment – Clascoterone 10 mg/g cream
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
The information in this document is correct at the time of publication and formulations may change. This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
The Formulary Assessment tool for Clascoterone 10 mg/g cream can be accessed here
Formulary amendments December 2025 & horizon scanning January 2026
Two new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in December 2025:
- Monthly formulary amendments – December 2025
- Monthly horizon scanning – January 2026